221 CRESCENT ST., WALTHAM, MA
Merger Completed: Apogee Therapeutics Merges with Andor LLC
Material disclosure
Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates
Apogee Therapeutics Enters IL-31R Antibody Discovery Agreement with Paragon
Voting Agreement Among Stockholders
Election Results from Apogee Therapeutics 2026 Annual Meeting
Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
Investor Presentation
Q2
Q1
FY 2025
Q3
FY 2024
Notice of Suspension of Duty to File Reports
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Merger Proxy Statement
Definitive Proxy Statement
Amended Schedule 13D - Ownership Report
Notification Filed by a National Security Exchange
Statement of Changes in Beneficial Ownership
PREM14A
S-1MEF